Use of Tetranectin, CA-125 and Casa to Predict Residual Tumor and Survival at Second- and Third-Look Operations for Ovarian Cancer
Tetranectin (TN), CA-125 and CASA were measured in serum prior to 63 second-look and 5 third-look operations for ovarian cancer. Patients with residual tumor had significantly lower levels of TN and higher levels of CASA and CA-125 compared with tumor-free patients. The predictive values PVPos = 100...
Gespeichert in:
| Veröffentlicht in: | Acta oncologica 1996, Vol.35 (1), p.63-69 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 69 |
|---|---|
| container_issue | 1 |
| container_start_page | 63 |
| container_title | Acta oncologica |
| container_volume | 35 |
| creator | Høgdall, Claus K. Høgdall, Estrid V.S. Hørding, Ulla Toftager-Larsen, Kim Arends, Jørgen Nørgaard-Pedersen, Bent Clemmensen, Inge |
| description | Tetranectin (TN), CA-125 and CASA were measured in serum prior to 63 second-look and 5 third-look operations for ovarian cancer. Patients with residual tumor had significantly lower levels of TN and higher levels of CASA and CA-125 compared with tumor-free patients. The predictive values PVPos = 100% and PVNeg = 50.9% were found for TN at 9.3 mg/1. For CASA, a predictive value PVPos = 100% was found at 10 U/ml with a corresponding PVNeg = 52.7%. At the cut-off 35 U/ml for CA-125, the PVPos was 100% and the PVNeg = 53.6%. By combining the markers, PVNeg increased to 61.7% with a PVPos on 100%. Significantly differences in survival were found by lifetable analysis between patients tested as positive and negative respectively for any of the markers. Using multivariate Cox analyses, it was found that every marker had an independent prognostic function for survival. |
| doi_str_mv | 10.3109/02841869609098481 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78053000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78053000</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-e786df987af77a6f1cd1672e48de9f494b156b33674bf94635ba1bc15dfd45ec3</originalsourceid><addsrcrecordid>eNp9kM1qGzEUhUVpSZ20D9BFQYuSVaaR5kca0VUw_QODQ-NAdsMd6QornRm5ksbQbZ68SmyyCXQluPc7R9JHyAfOPlecqUtWtjVvhRJMMdXWLX9FFlw0vChLcfeaLB73RQbu3pLTGO8ZY2UlmxNy0gquVF0uyMNtROot3WAKMKFObrqgy6uClw2FydAlRKDJ0-uAxulEf2F0ZoaBbubRhyfkZg57t88jSPQGtZ9M8TTfbF0wxcr733S9wwDJ-SlSm1PrPQQHUy6fNIZ35I2FIeL743lGbr993Sx_FKv195_Lq1WhKylTgbIVxqpWgpUShOXacCFLrFuDytaq7nkj-qoSsu6tqkXV9MB7zRtjTd2grs7I-aF3F_yfGWPqRhc1DkP-t59jJ1vWVFlRBvkB1MHHGNB2u-BGCH87zrpH790L7znz8Vg-9yOa58RRdN5_Ou4hahhslq1dfMbyvUpKlbEvB8xNWdQIW4QhbTUE7O79HKbs5z-P-AdcCJxL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78053000</pqid></control><display><type>article</type><title>Use of Tetranectin, CA-125 and Casa to Predict Residual Tumor and Survival at Second- and Third-Look Operations for Ovarian Cancer</title><source>Taylor & Francis</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Høgdall, Claus K. ; Høgdall, Estrid V.S. ; Hørding, Ulla ; Toftager-Larsen, Kim ; Arends, Jørgen ; Nørgaard-Pedersen, Bent ; Clemmensen, Inge</creator><creatorcontrib>Høgdall, Claus K. ; Høgdall, Estrid V.S. ; Hørding, Ulla ; Toftager-Larsen, Kim ; Arends, Jørgen ; Nørgaard-Pedersen, Bent ; Clemmensen, Inge</creatorcontrib><description>Tetranectin (TN), CA-125 and CASA were measured in serum prior to 63 second-look and 5 third-look operations for ovarian cancer. Patients with residual tumor had significantly lower levels of TN and higher levels of CASA and CA-125 compared with tumor-free patients. The predictive values PVPos = 100% and PVNeg = 50.9% were found for TN at 9.3 mg/1. For CASA, a predictive value PVPos = 100% was found at 10 U/ml with a corresponding PVNeg = 52.7%. At the cut-off 35 U/ml for CA-125, the PVPos was 100% and the PVNeg = 53.6%. By combining the markers, PVNeg increased to 61.7% with a PVPos on 100%. Significantly differences in survival were found by lifetable analysis between patients tested as positive and negative respectively for any of the markers. Using multivariate Cox analyses, it was found that every marker had an independent prognostic function for survival.</description><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.3109/02841869609098481</identifier><identifier>PMID: 8619942</identifier><identifier>CODEN: ACTOEL</identifier><language>eng</language><publisher>Basingstoke: Informa UK Ltd</publisher><subject>Adult ; Aged ; Antigens, Neoplasm - blood ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Blood Proteins - analysis ; CA-125 Antigen - blood ; Female ; Female genital diseases ; Follow-Up Studies ; Forecasting ; Gynecology. Andrology. Obstetrics ; Humans ; Infant, Newborn ; Lectins, C-Type ; Life Tables ; Medical sciences ; Middle Aged ; Mucin-1 - blood ; Multivariate Analysis ; Neoplasm Proteins - blood ; Neoplasm, Residual ; Ovarian Neoplasms - blood ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - surgery ; Prognosis ; Proportional Hazards Models ; Remission Induction ; Reoperation ; Sensitivity and Specificity ; Survival Rate ; Tumors</subject><ispartof>Acta oncologica, 1996, Vol.35 (1), p.63-69</ispartof><rights>1996 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1996</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-e786df987af77a6f1cd1672e48de9f494b156b33674bf94635ba1bc15dfd45ec3</citedby><cites>FETCH-LOGICAL-c377t-e786df987af77a6f1cd1672e48de9f494b156b33674bf94635ba1bc15dfd45ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/02841869609098481$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/02841869609098481$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,776,780,4010,27900,27901,27902,61194,61375</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3009779$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8619942$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Høgdall, Claus K.</creatorcontrib><creatorcontrib>Høgdall, Estrid V.S.</creatorcontrib><creatorcontrib>Hørding, Ulla</creatorcontrib><creatorcontrib>Toftager-Larsen, Kim</creatorcontrib><creatorcontrib>Arends, Jørgen</creatorcontrib><creatorcontrib>Nørgaard-Pedersen, Bent</creatorcontrib><creatorcontrib>Clemmensen, Inge</creatorcontrib><title>Use of Tetranectin, CA-125 and Casa to Predict Residual Tumor and Survival at Second- and Third-Look Operations for Ovarian Cancer</title><title>Acta oncologica</title><addtitle>Acta Oncol</addtitle><description>Tetranectin (TN), CA-125 and CASA were measured in serum prior to 63 second-look and 5 third-look operations for ovarian cancer. Patients with residual tumor had significantly lower levels of TN and higher levels of CASA and CA-125 compared with tumor-free patients. The predictive values PVPos = 100% and PVNeg = 50.9% were found for TN at 9.3 mg/1. For CASA, a predictive value PVPos = 100% was found at 10 U/ml with a corresponding PVNeg = 52.7%. At the cut-off 35 U/ml for CA-125, the PVPos was 100% and the PVNeg = 53.6%. By combining the markers, PVNeg increased to 61.7% with a PVPos on 100%. Significantly differences in survival were found by lifetable analysis between patients tested as positive and negative respectively for any of the markers. Using multivariate Cox analyses, it was found that every marker had an independent prognostic function for survival.</description><subject>Adult</subject><subject>Aged</subject><subject>Antigens, Neoplasm - blood</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Blood Proteins - analysis</subject><subject>CA-125 Antigen - blood</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Follow-Up Studies</subject><subject>Forecasting</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Lectins, C-Type</subject><subject>Life Tables</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mucin-1 - blood</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Proteins - blood</subject><subject>Neoplasm, Residual</subject><subject>Ovarian Neoplasms - blood</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Remission Induction</subject><subject>Reoperation</subject><subject>Sensitivity and Specificity</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1qGzEUhUVpSZ20D9BFQYuSVaaR5kca0VUw_QODQ-NAdsMd6QornRm5ksbQbZ68SmyyCXQluPc7R9JHyAfOPlecqUtWtjVvhRJMMdXWLX9FFlw0vChLcfeaLB73RQbu3pLTGO8ZY2UlmxNy0gquVF0uyMNtROot3WAKMKFObrqgy6uClw2FydAlRKDJ0-uAxulEf2F0ZoaBbubRhyfkZg57t88jSPQGtZ9M8TTfbF0wxcr733S9wwDJ-SlSm1PrPQQHUy6fNIZ35I2FIeL743lGbr993Sx_FKv195_Lq1WhKylTgbIVxqpWgpUShOXacCFLrFuDytaq7nkj-qoSsu6tqkXV9MB7zRtjTd2grs7I-aF3F_yfGWPqRhc1DkP-t59jJ1vWVFlRBvkB1MHHGNB2u-BGCH87zrpH790L7znz8Vg-9yOa58RRdN5_Ou4hahhslq1dfMbyvUpKlbEvB8xNWdQIW4QhbTUE7O79HKbs5z-P-AdcCJxL</recordid><startdate>1996</startdate><enddate>1996</enddate><creator>Høgdall, Claus K.</creator><creator>Høgdall, Estrid V.S.</creator><creator>Hørding, Ulla</creator><creator>Toftager-Larsen, Kim</creator><creator>Arends, Jørgen</creator><creator>Nørgaard-Pedersen, Bent</creator><creator>Clemmensen, Inge</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1996</creationdate><title>Use of Tetranectin, CA-125 and Casa to Predict Residual Tumor and Survival at Second- and Third-Look Operations for Ovarian Cancer</title><author>Høgdall, Claus K. ; Høgdall, Estrid V.S. ; Hørding, Ulla ; Toftager-Larsen, Kim ; Arends, Jørgen ; Nørgaard-Pedersen, Bent ; Clemmensen, Inge</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-e786df987af77a6f1cd1672e48de9f494b156b33674bf94635ba1bc15dfd45ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antigens, Neoplasm - blood</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Blood Proteins - analysis</topic><topic>CA-125 Antigen - blood</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Follow-Up Studies</topic><topic>Forecasting</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Lectins, C-Type</topic><topic>Life Tables</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mucin-1 - blood</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Proteins - blood</topic><topic>Neoplasm, Residual</topic><topic>Ovarian Neoplasms - blood</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Remission Induction</topic><topic>Reoperation</topic><topic>Sensitivity and Specificity</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Høgdall, Claus K.</creatorcontrib><creatorcontrib>Høgdall, Estrid V.S.</creatorcontrib><creatorcontrib>Hørding, Ulla</creatorcontrib><creatorcontrib>Toftager-Larsen, Kim</creatorcontrib><creatorcontrib>Arends, Jørgen</creatorcontrib><creatorcontrib>Nørgaard-Pedersen, Bent</creatorcontrib><creatorcontrib>Clemmensen, Inge</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Høgdall, Claus K.</au><au>Høgdall, Estrid V.S.</au><au>Hørding, Ulla</au><au>Toftager-Larsen, Kim</au><au>Arends, Jørgen</au><au>Nørgaard-Pedersen, Bent</au><au>Clemmensen, Inge</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Tetranectin, CA-125 and Casa to Predict Residual Tumor and Survival at Second- and Third-Look Operations for Ovarian Cancer</atitle><jtitle>Acta oncologica</jtitle><addtitle>Acta Oncol</addtitle><date>1996</date><risdate>1996</risdate><volume>35</volume><issue>1</issue><spage>63</spage><epage>69</epage><pages>63-69</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><coden>ACTOEL</coden><abstract>Tetranectin (TN), CA-125 and CASA were measured in serum prior to 63 second-look and 5 third-look operations for ovarian cancer. Patients with residual tumor had significantly lower levels of TN and higher levels of CASA and CA-125 compared with tumor-free patients. The predictive values PVPos = 100% and PVNeg = 50.9% were found for TN at 9.3 mg/1. For CASA, a predictive value PVPos = 100% was found at 10 U/ml with a corresponding PVNeg = 52.7%. At the cut-off 35 U/ml for CA-125, the PVPos was 100% and the PVNeg = 53.6%. By combining the markers, PVNeg increased to 61.7% with a PVPos on 100%. Significantly differences in survival were found by lifetable analysis between patients tested as positive and negative respectively for any of the markers. Using multivariate Cox analyses, it was found that every marker had an independent prognostic function for survival.</abstract><cop>Basingstoke</cop><pub>Informa UK Ltd</pub><pmid>8619942</pmid><doi>10.3109/02841869609098481</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0284-186X |
| ispartof | Acta oncologica, 1996, Vol.35 (1), p.63-69 |
| issn | 0284-186X 1651-226X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78053000 |
| source | Taylor & Francis; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Antigens, Neoplasm - blood Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Biomarkers, Tumor - blood Blood Proteins - analysis CA-125 Antigen - blood Female Female genital diseases Follow-Up Studies Forecasting Gynecology. Andrology. Obstetrics Humans Infant, Newborn Lectins, C-Type Life Tables Medical sciences Middle Aged Mucin-1 - blood Multivariate Analysis Neoplasm Proteins - blood Neoplasm, Residual Ovarian Neoplasms - blood Ovarian Neoplasms - drug therapy Ovarian Neoplasms - surgery Prognosis Proportional Hazards Models Remission Induction Reoperation Sensitivity and Specificity Survival Rate Tumors |
| title | Use of Tetranectin, CA-125 and Casa to Predict Residual Tumor and Survival at Second- and Third-Look Operations for Ovarian Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T23%3A21%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Tetranectin,%20CA-125%20and%20Casa%20to%20Predict%20Residual%20Tumor%20and%20Survival%20at%20Second-%20and%20Third-Look%20Operations%20for%20Ovarian%20Cancer&rft.jtitle=Acta%20oncologica&rft.au=H%C3%B8gdall,%20Claus%20K.&rft.date=1996&rft.volume=35&rft.issue=1&rft.spage=63&rft.epage=69&rft.pages=63-69&rft.issn=0284-186X&rft.eissn=1651-226X&rft.coden=ACTOEL&rft_id=info:doi/10.3109/02841869609098481&rft_dat=%3Cproquest_cross%3E78053000%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78053000&rft_id=info:pmid/8619942&rfr_iscdi=true |